Maharashtra FDA Warns Against Suspected Falsified Rabies Vaccine: Batch 1630T092
Quick note
Below is the official summary and the reference document preview. Use “Open PDF” for full screen view.
Schedule a Call Back
Summary
The Maharashtra FDA issued an alert on 28 September 2026 after issues emerged with a vial of rabies vaccine, batch number 1630T092. The batch in question was from the company, Serum Institute of India Pvt. Ltd., Pune; however, the manufacturer claimed that the batch number was not theirs.
The matter came to light when a hospital in West Bengal reportedly received a rabies vaccine vial without the accompanying diluent. After the manufacturer verified the issue, the Maharashtra FDA advised hospitals, pharmacies, vaccination centres and distributors not to use the identified batch.
The Maharashtra FDA alert regarding the rabies vaccine is aimed at ensuring that the suspected batch does not reach patients and helps in tracing the source of the batch. The alert also emphasizes the need for screening of vaccine batches, supplier verification, and record keeping in the pharmaceutical industry.
The Maharashtra FDA rabies vaccine alert 2026 concerns the identified batch, not all rabies vaccines. Anyone checking a suspected fake rabies vaccine in India should rely on the official batch warning and appropriate regulatory verification.
Maharashtra FDA Public Alert at a Glance
The public alert identifies the suspected product and outlines precautions healthcare institutions and pharmaceutical businesses should follow.
| Alert detail | Information |
| Issuing authority | Maharashtra Food and Drug Administration (FDA) |
| Document date | 28 September 2026 |
| Type of notice | Public alert regarding a suspected falsified vaccine |
| Vaccine | Rabies Vaccine, Human I.P. (Freeze-Dried) |
| Batch under alert | 1630T092 |
| Name printed on the questioned product | Serum Institute of India Pvt. Ltd., Pune |
| Reported concern | Batch number not traceable in the named manufacturer's records; vial reportedly supplied without diluent |
| Who should take precautions | Hospitals, vaccination centres, pharmacies, medical practitioners, wholesalers, distributors and the public |
| Main directions | Do not use the specified batch; quarantine and preserve stock; report suspected products |
| Legal nature | Batch-specific public health advisory, not a new drug licence registration requirement |
Important: This is a warning about a specific suspected vaccine batch. The notice does not state that every rabies vaccine or every product manufactured by Serum Institute of India is affected.
Why Did Maharashtra FDA Issue the Rabies Vaccine Alert?
The concern began with a complaint about a vaccine vial that reportedly arrived without its accompanying diluent. A diluent is the liquid used to prepare certain freeze-dried vaccines before administration.
The complaint came from 4033 Field Hospital, Sukna, Darjeeling, West Bengal. Upon verifying the product information, the manufacturer found discrepancies which made it doubt the authenticity of the vaccine.
1. Mismatch in Batch Number of the Product
The suspicious vial had batch number 1630T092 with the name of the manufacturer “Serum Institute of India Pvt. Ltd.”, Pune.
In their letter dated 24th September 2026, the manufacturer told Maharashtra FDA that they could not find the batch number in their manufacturing records.
The company also reported that it had not manufactured or released a rabies vaccine under that batch number.
This was a significant concern because the label identified a manufacturer whose records did not support the product's claimed origin.
2. The Vaccine Was Reportedly Received Without Diluent
The manufacturer also pointed out a difference in the product's supply arrangement.
According to its communication, the company's rabies vaccine is supplied with the corresponding diluent. The manufacturer described its standard arrangement as 50 vaccine units and 50 diluent units supplied in separate boxes.
Receiving a vaccine vial without the accompanying diluent was inconsistent with that arrangement.
Although this packaging discrepancy alone does not prove the product was falsified, it added to the concerns raised by the batch-number verification.
3. Maharashtra FDA Issued a Public Warning
After reviewing the manufacturer's information, Maharashtra FDA issued a public health advisory on the identified batch.
The authority warned healthcare institutions, medical practitioners, pharmacists, wholesalers, distributors and members of the public against using the suspected vaccine.
The alert aims to prevent further use or distribution of the questioned product while competent authorities examine the matter.
Details of the Suspected Falsified Rabies Vaccine
Identifying the correct product is especially important because the alert concerns one reported batch, not the entire rabies vaccine market.
The questioned vial contained the following particulars:
| Identification detail | Information appearing on or reported about the questioned vial |
| Product name | Rabies Vaccine, Human I.P. (Freeze-Dried) |
| Batch number | 1630T092 |
| Manufacturing date shown | February 2026 |
| Expiry date shown | January 2029 |
| Manufacturer name on label | Serum Institute of India Pvt. Ltd., Pune |
| Complaint source | 4033 Field Hospital, Sukna, Darjeeling, West Bengal |
| Packaging concern | Vial reportedly received without the accompanying diluent |
| Manufacturer verification | The named manufacturer reported that the batch had not been manufactured or released by it |
The questioned label shows the manufacturing and expiry dates. They have not been independently authenticated as genuine.
The manufacturer reported that the company had not manufactured or released the product bearing this batch number.
For a hospital, pharmacy or distributor checking its inventory, the batch number is therefore the most important detail to identify first.
Do not assume a product is genuine simply because its label carries the name of a recognised pharmaceutical manufacturer.
What Does the Maharashtra FDA Public Health Advisory Say?
The FDA has advised healthcare institutions and pharmaceutical businesses to take immediate precautions concerning batch 1630T092.
The main directions are explained below.
Do Not Use the Identified Vaccine Batch
The authority has advised that no rabies vaccine vial bearing batch number 1630T092 should be used, regardless of where it was purchased or obtained.
This means the source of procurement does not remove the concern about the identified product.
Separate Suspected Stock from Other Vaccines
Hospitals, vaccination centres, pharmacies, wholesalers and distributors have been advised to immediately segregate and quarantine any stock bearing the specified batch number.
Quarantining means keeping the product separate so it cannot be accidentally supplied, sold or administered.
Stop Sale and Distribution of the Suspected Product
The alert advises establishments to prevent the sale, distribution or administration of the identified vaccine.
Businesses should ensure that the relevant staff are aware of the warning and that suspected stock is not returned to normal inventory.
Preserve the Stock for Inspection
Maharashtra FDA has specifically advised against destroying, discarding or returning the suspected product through an unauthorised channel.
Instead, keep the product securely for inspection or investigation by the appropriate drug regulatory authorities.
Report Any Suspected Availability or Distribution
The authority has asked stakeholders to report suspected availability, sale, distribution or use of the identified batch to the nearest Maharashtra FDA office.
Available supplier details, distributor information and stock quantities should also be provided.
These precautions relate to the suspected product identified in the alert. They are not a general restriction on the use of all rabies vaccines.
Who Is Affected by the Maharashtra FDA Rabies Vaccine Alert?
The advisory applies to businesses and institutions that purchase, store, distribute or administer rabies vaccines.
| Stakeholder | Practical relevance of the FDA vaccine safety alert |
| Hospitals and vaccination centres | Identify and quarantine the named batch so it is not administered |
| Pharmacies and medical stores | Check stock and prevent supply of the questioned batch |
| Pharmaceutical wholesalers | Identify affected inventory and prevent further distribution |
| Vaccine suppliers and distributors | Check batch and procurement information and report suspected stock |
| Medical practitioners | Be aware of the warning and advise potentially affected patients appropriately |
| Patients and the public | Seek prompt medical advice if they may have received the identified batch |
The complaint originated in West Bengal, while the public alert was issued by the Maharashtra FDA. Anyone who encounters the specified batch should take the warning seriously and seek guidance from the appropriate drug regulatory authority.
Why This Matters for Pharmaceutical Businesses
Hospitals and pharmacies handle products that patients depend on for treatment and prevention. A problem with product identification or supply-chain records can therefore have serious consequences.
The incident shows why pharmaceutical businesses should know where their stock came from, which batches they hold and where products have been supplied.
For wholesalers and distributors, well-maintained purchase and distribution records make it easier to identify potentially affected stock.
For hospitals and vaccination centres, clear stock-handling procedures help prevent administering a questioned product.
These are practical lessons from the alert. They should not be confused with new licensing conditions introduced by the September 2026 notice.
How Can Hospitals and Pharmacies Check Rabies Vaccine Authenticity?
Checking the batch number is the first step, but it should not be the only check when there is doubt about a vaccine.
A rabies vaccine authenticity check may include rabies vaccine batch number verification, packaging details and supplier records. These checks help identify possible problems but do not replace confirmation by the manufacturer or drug regulatory authority.
Healthcare institutions and suppliers can use the following measures to identify possible inconsistencies.
- Look at the batch number. Verify the number written on the vial against the one that is stated in the public notice. Any vial having the batch number 1630T092 is under the FDA notice.
- Look at the manufacturer's information. Read the company's name and other details written on the label. If there is any doubt about the information, verify it through reliable sources.
- Examine the packaging and diluent. Determine if the product was provided in the right form along with the other components that were necessary. The absence of the diluent was one of the issues identified in this case.
- Investigate purchase and supplier information. Any invoices, shipping documents, and inventory records may assist in determining from where the vaccine was purchased.
- Send the product to the relevant authority. If the product seems suspicious or if it cannot be authenticated, then it should not be used while being investigated.
These checks can help identify possible problems, but they do not replace official product verification.
A vaccine cannot be declared authentic simply because its packaging looks normal or its label contains familiar company details.
What Should Hospitals, Pharmacies and Distributors Do Now?
If an establishment finds vaccine stock bearing batch number 1630T092, it should follow the precautions in the FDA alert.
A practical approach is to:
- Stop use immediately. Ensure that the identified vaccine is not administered, sold or distributed.
- Keep the suspected stock separate. Move it away from products available for normal use and clearly identify it as quarantined stock.
- Inform the relevant staff. Make sure pharmacy, procurement, warehouse and vaccination teams know about the warning.
- Check available records. Review purchase invoices, supplier information, batch details and stock quantities to establish the product's source.
- The product must neither be destroyed nor returned via any unauthorized route. It should be stored safely for inspection.
- Inform about the suspected stock. Approach the relevant drug regulatory authority with the product and supplier information.
- Cooperate with the investigation. Provide relevant information when authorised officials request it.
Institutions may also wish to review their internal processes for receiving vaccine stock and circulating drug safety alerts.
The most important point is that suspected products must not return to normal use simply because they have been placed in a separate storage area.
What Should Patients Do if They Received the Suspected Vaccine?
A patient who believes they may have received a rabies vaccine bearing batch number 1630T092 should contact their treating doctor or healthcare institution immediately.
If available, the patient can share the vaccination card, vaccination date, batch details, and the name of the hospital or pharmacy involved.
The healthcare professional can then assess the situation and advise on the appropriate course of action.
The original public alert also advises affected members of the public to contact the appropriate drug regulatory authority and provide details of where the product was obtained.
Patients should not decide on their own whether to stop, restart or repeat a rabies vaccination course.
Rabies is a serious disease, and treatment after possible exposure should not be delayed. The World Health Organization recommends prompt medical care and appropriate post-exposure prophylaxis following suspected rabies exposure.
Anyone undergoing rabies vaccination should continue to follow a qualified healthcare professional's advice.
The Maharashtra FDA warning does not mean that every person who has received a rabies vaccine is affected.
How to Report a Suspected Falsified Rabies Vaccine in Maharashtra
Maharashtra FDA has requested immediate reporting of any suspected sale, distribution, availability or use of the identified vaccine.
Hospitals, pharmacies, distributors and members of the public can report the matter to the nearest Food and Drug Administration office in Maharashtra.
When reporting suspected stock, the following information can help the authorities examine the matter:
- Product name and batch number.
- Quantity of suspected stock available.
- Name and details of the supplier or distributor.
- Source and date of procurement, where known.
- Relevant product or purchase records.
- Details of any suspected sale, distribution or use.
The alert expressly requests supplier or distributor information and the available quantity. Other supporting records may be useful, depending on the circumstances.
Businesses should keep the suspected product securely segregated until the appropriate authority provides further directions.
Regulatory Framework and Legal Implications for Pharmaceutical Businesses
The Maharashtra FDA public alert has been issued with reference to the Drugs and Cosmetics Act, 1940, and the applicable Drugs and Cosmetics Rules, 1945.
These laws regulate the manufacture, import, sale and distribution of drugs in India.
The Act includes provisions addressing misbranded, adulterated or spurious products. It also provides the legal basis for action where relevant violations are established.
In this case, the manufacturer reported that the questioned vaccine batch could not be matched with its records. Maharashtra FDA therefore treated the product as suspected of falsification.
However, a suspicion reported in a public alert is not the same as a completed regulatory finding.
The authority stated that appropriate regulatory and enforcement action would be taken as warranted by the applicable law and the outcome of the examination.
The public alert does not specify a new fine, registration fee, licence cancellation requirement or separate compliance deadline for pharmaceutical businesses.
Does the Alert Introduce Any New Drug License Requirement?
No new drug licence application or registration process is introduced by this public alert.
Businesses must continue to comply with the drug licensing requirements that already apply to their activities.
For example, businesses that retail or wholesale medicines generally need the appropriate drug sale licences under the applicable regulatory framework.
A business planning to enter pharmaceutical distribution may therefore need to consider the relevant wholesale drug licence, while an eligible pharmacy operator may need a retail drug licence.
These are existing licensing matters, not new requirements created by the rabies vaccine warning.
The incident nevertheless demonstrates why businesses should pay attention to supplier verification, product traceability and responsible stock handling alongside their licensing obligations.
What Is the Current Status of the Suspected Rabies Vaccine Investigation?
According to the FDA Maharashtra Public Alert issued on 28 September 2026, it was conducting additional regulatory inspections and investigations.
The authority may take or continue any action under the Drugs and Cosmetics Act and Rules, if required.
However, as of 29 October 2026, no official investigation result relating to batch number 1630T092 was found in the official sources examined for this article.
The product is therefore described here as a suspected falsified rabies vaccine, in line with the original public alert.
Hospitals, pharmacies and pharmaceutical suppliers should refer to any subsequent official directions, if issued, before deciding what to do with the questioned stock.
How Corpseed Can Help with Drug Licensing and Pharmaceutical Compliance?
Running a pharmacy, medical distribution business or other pharmaceutical operation involves more than obtaining a licence. Businesses also need to understand which regulatory requirements apply to their activities and maintain the documentation required under the relevant laws.
For entrepreneurs entering the pharmaceutical sector and existing businesses seeking licensing assistance, Corpseed provides support with relevant drug licence applications and documentation.
Businesses seeking drug licence consultancy, drug licence application assistance or pharmaceutical regulatory compliance services can obtain help with existing licensing and documentation requirements relevant to their activities. Depending on the business, the requirements may involve wholesale drug licence registration, a retail drug licence application or appropriate FDA drug licence consultancy; these are not new obligations created by this public alert.
- Drug Licence Registration: Businesses seeking the appropriate licence to manufacture, sell or distribute medicines can obtain assistance with identifying applicable licensing requirements and preparing their applications.
- Wholesale Drug Licence: Pharmaceutical wholesalers and distributors can seek guidance on the documents, eligibility conditions and application requirements relevant to their wholesale operations.
- Retail Drug Licence: Businesses planning to open or operate a medical store can obtain assistance with applicable retail drug licensing requirements and documentation.
- Regulatory Documentation Support: Businesses can seek assistance with understanding the records and application documents relevant to their specific licensing needs.
Professional consultancy is optional and does not replace the role of the government licensing or enforcement authority.
Need Assistance with Drug Licensing in India?
Whether you plan to open a pharmacy, establish a pharmaceutical wholesale business, or apply for the appropriate drug licence, understanding the requirements before submitting an application can help you avoid unnecessary documentation issues.
Connect with Corpseed for assistance with drug licence registration, wholesale drug licensing and relevant pharmaceutical regulatory documentation.
Key Takeaways
The Maharashtra FDA notice of 28 September 2026 relates to Rabies Vaccine, Human I.P. (Freeze-Dried), batch number 1630T092.
The manufacturer reported that the batch number was not found in its records and that the questioned product had not been manufactured or released by the company.
Healthcare institutions, pharmacies and distributors have been advised not to use or supply the identified batch. Any available stock should be quarantined, preserved and reported to the appropriate drug regulatory authority.
Patients who believe they received the suspected product should seek prompt medical advice.
For pharmaceutical businesses, the alert reinforces the importance of checking product particulars, maintaining supply records and responding promptly to official safety warnings.
Schedule a Call Back
Document Preview
Embedded reference document
Related
Explore more updates from the same department.
